Apogee Therapeutics reported net income of -$85.85M for the quarter ended Jun 2026. This income statement covers 17 quarters of results from Jun 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & Cost | |||||||||||||||||
| Interest income | |||||||||||||||||
| Interest Income - Total | -6.09M | -10.31M | -9.67M | -8.68M | -7.84M | -7.14M | -6.32M | -8.73M | |||||||||
| Interest expenses | |||||||||||||||||
| Interest ExpensesInterest Expense | 1.58M | ||||||||||||||||
| Operating Items | |||||||||||||||||
| Research & DevelopmentR&D | 1.45M | 9.88M | 12.21M | 8.46M | 13.95M | 17.07M | 28.95M | 28.72M | 33.21M | 45.71M | 60.23M | 46.39M | 55.70M | 54.18M | 58.44M | 60.82M | 67.30M |
| Selling, General & AdministrativeSG&A | 0.37M | 0.62M | 1.89M | 4.20M | 4.94M | 7.24M | 8.20M | 9.46M | 10.92M | 12.97M | 15.65M | 16.71M | 17.46M | 17.10M | 19.61M | 21.95M | 24.34M |
| Other Operating ExpensesOther Opex | 4.36M | ||||||||||||||||
| Operating ExpensesOpex | 1.82M | 10.51M | 14.10M | 12.66M | 18.89M | 24.30M | 37.16M | 38.18M | 44.12M | 58.69M | 75.88M | 63.10M | 73.17M | 71.28M | 78.06M | 82.77M | 96.00M |
| Operating IncomeOp. Inc | -1.82M | -10.51M | -14.10M | -12.66M | -18.89M | -24.30M | -37.16M | -38.18M | -44.12M | -58.69M | -75.88M | -63.10M | -73.17M | -71.28M | -78.06M | -82.77M | -96.00M |
| EBIT | -1.82M | -10.51M | -14.10M | -12.66M | -18.89M | -24.30M | -37.16M | -38.18M | -44.12M | -58.69M | -75.88M | -63.10M | -73.17M | -71.28M | -78.06M | -82.77M | -96.00M |
| Non-operating items | |||||||||||||||||
| Non Operating Interest Expenses | 1.58M | ||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.13M | 3.46M | 5.42M | -0.51M | -0.11M | 9.67M | 8.68M | 0.16M | 7.14M | 6.32M | 8.73M | -1.83M | 11.81M | ||||
| Other Non Operating IncomeOther Non Op Inc. | -9.15M | 0.09M | 0.13M | 3.46M | 5.42M | 6.09M | 10.31M | 9.67M | 8.68M | 7.84M | 7.14M | 6.32M | 8.73M | 8.74M | 10.23M | ||
| Net income details | |||||||||||||||||
| EBT | -1.82M | -10.51M | -14.10M | -12.53M | -18.89M | -20.84M | -31.73M | -32.09M | -33.82M | -49.02M | -67.20M | -55.26M | -66.02M | -64.96M | -69.33M | -74.03M | -85.78M |
| Tax ProvisionsTaxes | -38.25M | 0.08M | 0.07M | 0.06M | -53.88M | 0.08M | 0.08M | ||||||||||
| Profit After TaxPAT | -1.82M | -19.66M | -14.01M | -12.53M | -18.89M | -20.84M | -31.73M | -32.09M | -33.82M | -49.02M | -67.22M | -55.34M | -66.10M | -65.02M | -69.34M | -74.11M | -85.85M |
| Income from Continuing OperationsIncome (Continuing) | -1.82M | -10.51M | -14.10M | -12.53M | -18.89M | -20.84M | -31.73M | -32.09M | -33.82M | -49.02M | -28.95M | -55.34M | -66.10M | -65.02M | -15.44M | -74.11M | -85.85M |
| Consolidated Net IncomeConsol Net Inc. | -1.82M | -10.51M | -14.10M | -12.53M | -18.89M | -20.84M | -31.73M | -32.09M | -33.82M | -49.02M | -28.95M | -55.34M | -66.10M | -65.02M | -15.44M | -74.11M | -85.85M |
| Income towards Parent CompanyParent Net Inc | -1.82M | -10.51M | -14.10M | -12.53M | -18.89M | -20.84M | -31.73M | -32.09M | -33.82M | -49.02M | -28.95M | -55.34M | -66.10M | -65.02M | -15.44M | -74.11M | -85.85M |
| Net Income towards Common StockholdersNet Income | -1.82M | -19.66M | -14.01M | -12.53M | -18.89M | -20.84M | -31.73M | -32.09M | -33.82M | -49.02M | -67.22M | -55.34M | -66.10M | -65.02M | -69.39M | -74.11M | -85.85M |
| Additional items | |||||||||||||||||
| EPS (Basic) | -1.45 | -9.46 | -5.69 | -2.51 | -3.78 | -0.51 | -1.27 | -0.64 | -0.60 | -0.86 | -1.22 | -0.95 | -1.13 | -1.11 | -1.14 | -1.06 | -1.14 |
| EPS (Diluted) | -1.45 | -9.46 | -5.69 | -2.51 | -3.78 | -0.51 | -1.27 | -0.64 | -0.60 | -0.86 | -1.22 | -0.95 | -1.13 | -1.11 | -1.14 | -1.06 | -1.14 |
| Shares Outstanding | 1.25M | 2.08M | 2.46M | 5.00M | 5.00M | 41.23M | 25.01M | 50.19M | 56.52M | 56.80M | 55.19M | 58.20M | 58.43M | 58.77M | 60.69M | 69.67M | 75.44M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 1.25M | 2.08M | 2.46M | 5.00M | 5.00M | 41.23M | 25.01M | 50.19M | 56.52M | 56.80M | 55.19M | 58.20M | 58.43M | 58.77M | 60.69M | 69.67M | 75.44M |
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 1.25M | 2.08M | 2.46M | 5.00M | 5.00M | 48.02M | 25.01M | 56.37M | 56.68M | 56.90M | 58.06M | 58.30M | 58.56M | 59.32M | 68.40M | 74.88M | 75.34M |
| EBITDA | -1.82M | -10.51M | -14.10M | -12.66M | -18.89M | -24.30M | -37.16M | -38.18M | -44.12M | -58.69M | -75.88M | -63.10M | -73.17M | -71.28M | -78.06M | -82.77M | -96.00M |